1558. A Population Pharmacokinetic Model for Posaconazole Intravenous Solution and Oral Powder for Suspension Formulations in Pediatric Patients With Neutropenia

Por Winchell, Gregory A, de Greef, Rik, Wrishko, Rebecca E, Mangin, Eric, Waskin, Hetty, Bruno, Christopher
Publicado no Open Forum Infect Dis (2019)

Tadalafil pharmacokinetics in healthy subjects

Por Forgue, S Thomas, Patterson, Beverley E, Bedding, Alun W, Payne, Christopher D, Phillips, Diane L, Wrishko, Rebecca E, Mitchell, Malcolm I
Publicado em 2006

Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection

Por Yee, Ka Lai, Kleijn, Huub Jan, Kerbusch, Thomas, Matthews, Randolph P., Dorr, Mary Beth, Garey, Kevin W., Wrishko, Rebecca E.
Publicado no Antimicrob Agents Chemother (2019)

Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics

Por Forgue, S Thomas, Phillips, Diane L, Bedding, Alun W, Payne, Christopher D, Jewell, Hayley, Patterson, Beverley E, Wrishko, Rebecca E, Mitchell, Malcolm I
Publicado em 2007

Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open‑Label, Fixed-Sequence Trials in Healthy Subjects

Por Wrishko, Rebecca E., McCrea, Jacqueline B., Yee, Ka Lai, Liu, Wen, Panebianco, Deborah, Mangin, Eric, Chakravarthy, Manu, Martinez-Cantarin, Maria P., Kraft, Walter K.
Publicado no Clin Drug Investig (2019)